Discovery and pharmacological characterization of aryl piperazine and piperidine ethers as dual acting norepinephrine reuptake inhibitors and 5-HT1A partial agonists

Bioorganic and Medicinal Chemistry Letters

Volumn 19, Issue 23, 2009, Pages 6604-6607

  Gray, David L ^a   Xu, Wenjian ^a   Campbell, Brian M ^a   Dounay, Amy B ^a   Barta, Nancy ^a   Boroski, Susan ^a   Denny, Lynne ^a   Evans, Lori ^a   Stratman, Nancy ^a   Probert, Al ^a  

^a PFIZER INC   (United States)

Author keywords

5 HT1A agonist; 5 Hydroxytryptamine 1A; ADHD; DAT; Depression; NET; Norepinephrine reuptake inhibitor; NRI; SERT

Indexed keywords

BENZYL DERIVATIVE; DIPHENYL ETHER; DOPAMINE TRANSPORTER; NORADRENALIN TRANSPORTER; NORADRENALIN UPTAKE INHIBITOR; PARTIAL AGONIST; PIPERAZINE DERIVATIVE; PIPERIDINE DERIVATIVE; SEROTONIN 1A AGONIST; SEROTONIN 1A RECEPTOR; SEROTONIN TRANSPORTER; THIOMORPHOLINE;

ANIMAL EXPERIMENT; ARTICLE; BINDING AFFINITY; CENTRAL NERVOUS SYSTEM; CONCENTRATION RESPONSE; DRUG DESIGN; DRUG PENETRATION; DRUG POTENCY; DRUG RECEPTOR BINDING; DRUG SCREENING; DRUG STRUCTURE; DRUG SYNTHESIS; DRUG TARGETING; IN VIVO STUDY; NONHUMAN; PREFRONTAL CORTEX; RAT; RECEPTOR OCCUPANCY; SUZUKI REACTION;

DOPAMINE; DRUG DISCOVERY; ETHERS; MOLECULAR STRUCTURE; NEUROTRANSMITTER UPTAKE INHIBITORS; PIPERAZINES; PIPERIDINES; RECEPTOR, SEROTONIN, 5-HT1A; SEROTONIN PLASMA MEMBRANE TRANSPORT PROTEINS; STEREOISOMERISM; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 71749121467     PISSN: 0960894X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bmcl.2009.10.014     Document Type: Article

References (38)

1. Baldessarini R.J. In: Bruton L.L., Lazo J.S., and Parker K.L. (Eds). The Pharmacological Basis of Therapeutics. 11th ed. (2006), McGraw-Hill 429
2. A selection of recent medicinal chemistry reports on NRIs and dual-acting NRIs:. Liu S., and Molino B.F. Annu. Rep. Med. Chem. 42 (2007) 13
3. McComas C.C., Vu A.T., Mahaney P.E., Cohn S.T., Fensome A., Marella M.A., Nogle L., Trybulski E.J., Ye F., Zhang P., Alfinito P., Bray J., Johnston G., Koury E., and Deecher D.C. Bioorg. Med. Chem. Lett. 18 (2008) 4929
4. Xu W., Gray D.L., Glase S.A., and Barta N.S. Bioorg. Med. Chem. Lett. 18 (2008) 5550
5. Hudson S., Kiankarimi M., Eccles W., Mostofi Y.S., Genicot M.J., Dwight W., Fleck B.A., Gogas K., and Wade W.S. Bioorg. Med. Chem. Lett. 18 (2008) 4495
6. Grace H., Bray J.A., Burroughs K.D., Cosmi S.A., Leventhal L., Koury E.J., Zhang Y., Mugford C.A., Ho D.M., Rosenzweig-Lipson S.J., Platt B., Smith V.A., and Deecher D.C. J. Med. Chem. 51 (2008) 4038
7. Whitlock G.A., Fish P.V., Fray M.J., Stobie A., and Wakenhut F. Bioorg. Med. Chem. Lett. 18 (2008) 2896
8. Gray D.L. In: Li J., and Johnson D. (Eds). The Art of Drug Synthesis (2007), Wiley 241
9. Weikop P., Kehr J., and Scheel-Krüger J. J. Psychopharmacol. 21 (2007) 795
10. Bourin M., Chenu F., Prica C., and Hascoet M. Psychopharmacology 206 (2009) 97
11. Ago Y., Koyama Y., Baba A., and Matsuda T. Neuropharmacology 45 (2003) 1050
12. Personal Communication, Brian Campell, Pfizer Global Research and Development, Groton, Connecticut, USA.
13. Jensen N.H., Rodriguiz R.M., Caron M.G., Wetsel W.C., Rothman R.B., and Roth B.L. Neuropsychopharmacology 33 (2008) 2303
14. Fliri A.F., Loging W.T., Thadeio P.F., and Volkmann R.A. J. Med. Chem. 48 (2005) 6918
15. Dounay A.B., Barta N.S., Bikker J.A., Borosky S.A., Campbell B.M., Crawford T., Denny L., Evans L.M., Gray D.L., Lee P., Lenoir E.A., and Xu W. Bioorg. Med. Chem. Lett. 19 (2009) 1159
16. Siracusa M.A., Salerno L., Modica M.N., Pittala V., Romeo G., Amato M.E., Nowak M., Bojarski A.J., Mereghetti I., Cagnotto A., and Mennini T. J. Med. Chem. 51 (2008) 4529
17. Howard, H. R. WO patent 9814433, 1998.
18. Pessoa-Mahana H., Araya-Maturana R., Claudio S.B., and Pessoa-Mahana C.D. Mini-Rev. Med. Chem. 3 (2003) 77
19. Murasaki M., and Miura S. Prog. Neuro-Psychopharmacol. Biol. Psych. 16 (1992) 833
20. Thomas G.H., Babbs A.J., Chatfield R.E., Krulle T.M., Widdowson P.S., Provost D., and McCormack J.G. Obesity 17 (2009) 467
21. Collantes, E. M.; Ortwine, D. F. Abstracts of Papers, 238th ACS National Meeting, Washington, DC, United States, March 16-20, 2009; COMP-229.
22. 1A = 14 nM).
23. Monoamine binding assay: Homogenized paste prepared from HEK293 cell lines expressing human clones for NE, DA, and 5HT transporters was incubated with drug and 50 pM [125I]-RTI-55 for 90 min at rt in PEI coated FlashPlates. Binding was terminated by assay volume withdraw with plates subsequently counted for beta emissions. Nonspecific binding was determined in the presence of selective inhibitors desipramine, GBR12909 and citalopram.
24. 1A binding assay according to published protocol:. Graham J.M., Coughenour L.L., Barr B.M., Rock D.L., and Nikam S.S. Bioorg. Med. Chem. Lett. 18 (2008) 489
25. Dyck B., Parker J., Phillips T., Carter L., Murphy B., Summers R., Hermann J., Baker T., Cismowski M., Saunders J., and Goodfellow V. Bioorg. Med. Chem. Lett. 21 (2003) 3793
26. Aryl piperidine benzyl alcohol 4 was prepared starting from 2-bromobenzaldehyde by the method outlined in Scheme 2.
27. 3 in MeOH.
28. Martin G.E., Elgin Jr. R.J., Mathiasen J.R., Davis C.B., Kesslick J.M., Baldy W.J., Shank R.P., DiStefano D.L., Fedde C.L., and Scott M.K. J. Med. Chem. 42 (1989) 1052
29. Richardson T.I., Ornstein P.L., Briner K., Fisher M.J., Backer R.T., Biggers C.K., Clay M.P., Emmerson P.J., Hertel L.W., Hsiung H.M., Husain S., Kahl S.D., Lee J.A., Lindstrom T.D., Martinelli M.J., Mayer J.P., Mullaney J.T., O'Brien T.P., Pawlak J.M., Revell K.D., Shah J., Zgombick J.M., Herr R.J., Melekhov A., Sampson P.B., and King C.-H.R. J. Med. Chem. 47 (2004) 744
30. Komoto T., Hirota H., Otsuka M., Kotake J., Hasegawa S., Koya H., Sato S., and Sakamoto T. Chem. Pharm. Bull. 48 (2000) 1978
31. Compound 14 was purchased from a commercial source.
32. Eastwood P.R. Tetrahedron Lett. 41 (2000) 3705
33. Fisher M.B., Henne K.R., and Boer J. Curr. Opin. Drug Disc. 9 (2006) 101
34. Buck E., Song Z.J., Tschaen D., Dormer P.G., Volante R.P., and Reider P.J. Org. Lett. 4 (2002) 1623
35. 1A (FLIPR assay) see Ref. 10a.
36. Monoamine uptake: HEK293 cell lines expressing human clones for NE, DA, and 5HT transporters were used to evaluate monamine reuptake inhibition. Cell suspensions were filter harvested following a 20 minute, RT exposure to tritiated versions of NE (100 nM), DA (50 nM), or 5HT (25 nM) in the presence or absence of test agents. Non-specific uptake was determined in the presence of selective antagonists atomoxetine, GBR12909 and citalopram. (c) HLM assay expressed as apparent intrinsic clearance (uncorrected for microsomal binding): Riley, R. J.; McGinnity, D. F.; Austin, R. P. Drug. Metab. Dispos. 2005, 33, 1304.
37. Grimwood S., and Hartig P.R. Pharmacol. Therap. 122 (2009) 281
38. 1A SEM = 0.6% (n = 4), NET SEM = 1.5% (n = 4). IACUC approved procedures were carried out in compliance with the NIH Guide for the Care and Use of Laboratory Animals (1985).